Ontology highlight
ABSTRACT: Purpose
Despite superiority of tamsulosin-dutasteride combination therapy versus monotherapy for lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH), patients at risk of disease progression are often initiated on ?-blockers. This study evaluated the impact of initiating tamsulosin monotherapy prior to switching to tamsulosin-dutasteride combination therapy versus immediate combination therapy using a longitudinal model describing International Prostate Symptom Score (IPSS) trajectories in moderate/severe LUTS/BPH patients at risk of disease progression.Methods
Clinical trial simulations (CTS) were performed using data from 10,238 patients from Phase III/IV dutasteride trials. The effect of varying disease progression rates was explored by comparing profiles on- and off-treatment. CTS scenarios were investigated, including a reference (immediate combination therapy) and six alternative virtual treatment arms (delayed combination therapy of 1-24 months). Clinical response (??25% IPSS reduction relative to baseline) was analysed using log-rank test. Differences in IPSS relative to baseline at various on-treatment time points were assessed by t tests.Results
Delayed combination therapy initiation led to significant (p?ConclusionsCTS allows systematic evaluation of immediate versus delayed combination therapy. Immediate response to ?-blockers is not predictive of long-term symptom improvement. Observed IPSS differences between immediate and delayed combination therapy (6-24 months) are statistically significant.
SUBMITTER: D'Agate S
PROVIDER: S-EPMC6994451 | biostudies-literature | 2020 Feb
REPOSITORIES: biostudies-literature
D'Agate Salvatore S Wilson Timothy T Adalig Burkay B Manyak Michael M Palacios-Moreno Juan Manuel JM Chavan Chandrashekhar C Oelke Matthias M Roehrborn Claus C Della Pasqua Oscar O
World journal of urology 20190511 2
<h4>Purpose</h4>Despite superiority of tamsulosin-dutasteride combination therapy versus monotherapy for lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH), patients at risk of disease progression are often initiated on α-blockers. This study evaluated the impact of initiating tamsulosin monotherapy prior to switching to tamsulosin-dutasteride combination therapy versus immediate combination therapy using a longitudinal model describing International Prostate Symptom Sco ...[more]